This page lists project-relevant scientific publications authored by the PaVe-GT project team.

2023
Successfully Navigating FDA Orphan Drug and Rare Pediatric Disease Designations for AAV9-hPCCA Gene Therapy: The NIH PaVe-GT Experience
Richa M. Lomash, Oleg Shchelochkov, Randy J. Chandler, Charles P. Venditti, Anne Pariser, and Elizabeth Ottinger
2020
The Platform Vector Gene Therapies (PaVe-GT) Project: Increasing the efficiency of adeno-associated virus (AAV) gene therapy clinical trial startup
Philip J. Brooks, Elizabeth A. Ottinger, Deanna Portero, Richa Madan Lomash, Asaf Alimardanov, Pramod Terse, Xin Xu, Randy J. Chandler, Janelle Geist Hauserman, Eric Esposito, Carsten G. Bönnemann, Charles P. Venditti, Christopher P. Austin, Anne…
2019
2016
Gene Therapy: The View from NCATS
Philip J. Brooks, N. Nora Yang, Christopher P. Austin
2010
Adeno-Associated Virus Serotype 8 Gene Transfer Rescues a Neonatal Lethal Murine Model of Propionic Acidemia
Randy J. Chandler, Suma Chandrasekaran, Nuria Carrillo-Carrasco, Julien S. Senac, Sean E. Hofherr, Michael A. Barry, and Charles P. Venditti
Subscribe
Sign-up for PaVe-GT updates.

Subscribe

Pave-GT Resources
Rare Pediatric Disease (RPD) Designation Request for AAV9-hPCCA

This pdf file contains the RPD designation request for AAV9-hPCCA (NCATSBL-0746) and associated communications between NCATS and FDA OOPD.

Orphan Drug Designation (ODD) Request for AAV9-hPCCA

This pdf file contains the ODD request for AAV9-hPCCA (NCATSBL-0746) and associated communications between NCATS and FDA OOPD.

Partners
National Institutes of Health